Table 2 Distribution of tumor characteristics and CAP1 tumor-specific expression
|  | Patients with tumor in TMA (n = 718) |  | |||||
|---|---|---|---|---|---|---|---|
Patient characteristics | All patients | Low CAP1 | Moderate CAP1 | High CAP1 | Ptrend | Non-assessable | Not included |
n (%) or median (IQR) | (n = 910) | (n = 106) | (n = 273) | (n = 290) | (n = 49) | in TMA (n = 192) | |
Age at diagnosis | |||||||
 Continuous [years] | 65.0 (60.0–71.6) | 65.4 (60.8–73.3) | 66.6 (61.4–72.3) | 63.9 (58.8–69.5) | < 0.001a | 60.7 (55.0–66.4) | 65.6 (60.4–71.9) |
Tumor size [mm] | |||||||
 ≤ 20 | 637 (71.8) | 64 (60.4) | 189 (69.5) | 205 (71.2) | 0.066b | 40 (83.3) | 139 (80.3) |
 > 20 | 250 (28.2) | 42 (39.6) | 83 (30.5) | 83 (28.8) | 8 (16.7) | 34 (19.7) | |
 Missing | 19 | 0 | 0 | 0 |  | 0 | 19 |
Axillary node involvement | |||||||
 Negative | 557 (68.0) | 65 (63.7) | 168 (63.9) | 181 (67.0) | 0.453b | 36 (80.0) | 107 (77.0) |
 Positive (≥ 1) | 262 (32.0) | 37 (36.3) | 95 (36.1) | 89 (33.0) | 9 (20.0) | 32 (23.0) | |
 Missing | 53 | 0 | 0 | 0 |  | 0 | 53 |
Histological grade | |||||||
 I | 227 (27.2) | 12 (11.4) | 55 (20.6) | 99 (34.5) | < 0.001b | 14 (33.3) | 47 (35.1) |
 II | 392 (46.9) | 48 (45.7) | 128 (47.9) | 138 (48.1) | 17 (40.5) | 61 (45.5) | |
 III | 216 (25.9) | 45 (42.9) | 84 (31.5) | 50 (17.4) | 11 (26.2) | 26 (19.4) | |
 Missing | 75 | 1 | 6 | 3 |  | 7 | 58 |
Ki67 status | |||||||
 Low | 258 (40.7) | 27 (30.7) | 62 (29.2) | 118 (54.4) | < 0.001b | 11 (39.3) | 40 (45.5) |
 Intermediate | 196 (31.0) | 26 (29.5) | 76 (35.8) | 65 (30.0) | 6 (21.4) | 23 (26.1) | |
 High | 179 (28.3) | 35 (39.8) | 74 (34.9) | 34 (15.7) | 11 (39.3) | 25 (28.4) | |
 Missing | 277 | 18 | 61 | 73 |  | 21 | 104 |
ER status | |||||||
 Positive (> 10%) | 701 (88.8) | 79 (79.0) | 235 (90.0) | 246 (90.1) | 0.014b | 31 (81.6) | 110 (94.0) |
 Negative (≤ 10%) | 88 (11.2) | 21 (21.0) | 26 (10.0) | 27 (9.9) | 7 (18.4) | 7 (6.0) | |
 Missing | 121 | 6 | 12 | 17 |  | 11 | 75 |
PR status | |||||||
 Positive (> 10%) | 438 (58.2) | 47 (49.0) | 165 (65.7) | 147 (56.5) | 0.729b | 19 (50.0) | 60 (56.1) |
 Negative (≤ 10%) | 314 (41.8) | 49 (51.0) | 86 (34.3) | 113 (43.5) | 19 (50.0) | 47 (43.9) | |
 Missing | 158 | 10 | 22 | 30 |  | 11 | 85 |
HER2 status | |||||||
 HER2+ | 65 (9.2) | 14 (16.9) | 19 (7.9) | 21 (8.3) | 0.071b | 3 (9.1) | 8 (8.1) |
 HER2− | 645 (90.8) | 69 (83.1) | 223 (92.1) | 232 (91.7) | 30 (90.9) | 91 (91.9) | |
 Missing | 200 | 23 | 31 | 37 |  | 16 | 93 |
Molecular subtypes | |||||||
 Luminal A-like | 352 (55.4) | 29 (37.2) | 110 (49.3) | 148 (66.4) | < 0.001b | 13 (46.4) | 52 (62.7) |
 Luminal B-like | 159 (25.0) | 21 (26.9) | 70 (31.4) | 38 (17.0) | 9 (32.1) | 21 (25.3) | |
 HER2+ | 65 (10.2) | 14 (17.9) | 19 (8.5) | 21 (9.4) | 3 (10.7) | 8 (9.6) | |
 Triple-negative | 59 (9.3) | 14 (17.9) | 24 (10.8) | 16 (7.2) | 3 (10.7) | 2 (2.4) | |
 Missing | 275 | 28 | 50 | 67 |  | 21 | 109 |